CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Bangkok Tenofovir Study : PrEP for HIV prevention among people who inject drugs
-
June 2013
[PDF-130.52 KB]
Details:
-
Alternative Title:Bangkok Tenofovir Study : PrEP for HIV prevention among people who inject drugs
-
Corporate Authors:
-
Description:Daily oral PrEP (pre-exposure prophylaxis) with a tablet containing tenofovir disoproxil fumarate (tenofovir, marketed in the United States under the brand name Viread®) was found to reduce the risk of acquiring HIV by approximately 49 percent in a study of 2,413 men and women who inject drugs in Bangkok, Thailand. Those who took the medication consistently had higher levels of protection, similar to findings previously reported from other PrEP trials. In a separate analysis of participants known to be adherent, because they were observed taking their medication and had tenofovir detected in their blood, the risk of HIV acquisition was reduced by approximately 74 percent.
This is the first study to report results of PrEP efficacy among people who inject drugs. Previous studies have found that PrEP with tenofovir – alone or in combination with emtricitabine (brand name Truvada®) – can reduce the risk of sexual transmission of HIV among heterosexuals and men who have sex with men.
-
Subjects:
-
Document Type:
-
Place as Subject:
-
Pages in Document:3 numbered pages
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
